Hemophilia A - Pipeline Review, H1 2018: Crucial Insights Compiled in a New Business Study for Healthcare
Hemophilia, a critical medical condition, characterized by spontaneous hemorrhage, easy bruising, and poor clotting, triggered by deficient FVIII. Pharmaceutical companies and research institutes are carrying out judicious research in drug innovation pertaining to FVIII. To understand current developments in hemophilia A therapeutics, Market Research Hub (MRH) has added a new study titled, 'Hemophilia A - Pipeline Review, H1 2018', to its repository.
View full press release